APHTHASOL
LOE Approachingamlexanox
NDADENTALPASTEPriority Review
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APHTHASOL (amlexanox) is a topical dental paste approved in 1996 for the treatment of aphthous ulcers (canker sores) in the oral cavity. The exact mechanism of action remains proprietary, but the drug is believed to work through anti-inflammatory and immunomodulatory pathways. It is applied directly to oral lesions to accelerate healing and reduce pain.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling a consolidating team focused on defense and cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
APHTHASOL offers limited career growth opportunities given its mature, niche position with zero linked job postings. Roles on this product typically focus on defensive sales strategy, payer negotiations, and cost management rather than innovation or market expansion.
Field Sales RepresentativeBrand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.